MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jaci.2026.06.015

Медицинская библиотека · The Journal of allergy and clinical immunology · 2026

AMPK-driven immunometabolic reprogramming enhances CD19+CD21hiCD24hi regulatory B-cell-mediated suppression of atopic dermatitis.

Lee Seung Taek, Kim Ha Eun, Kim So-Yeon, Lee Jong Yeong, Nam Kyung-Hwa, Kim Sang-Hyun, Park Jun-Young, Choi Jin Kyeong

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Atopic dermatitis (AD) is characterized by dysregulated immune responses and persistent inflammation. Regulatory B (Breg) cells suppress inflammation, but the metabolic mechanisms constraining their function in AD remain unclear.

OBJECTIVE

We sought to define whether immunometabolic regulation governs Breg cell differentiation and function in AD.

METHODS

Mouse and human B cells were stimulated with the adenosine monophosphate-activated protein kinase (AMPK) activator 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR) under inflammatory conditions, with genetic and pharmacologic perturbations. Functional and mechanistic analyses were performed with coculture systems, a 2,4-dinitrochlorobenzene and Dermatophagoides farinae extract-induced murine model of AD, adoptive transfer approaches, adoptive transfer, and human peripheral blood mononuclear cells from patients with AD.

RESULTS

AICAR treatment or adoptive transfer of AICAR-induced Breg cells significantly attenuated AD-like inflammation, whereas AMPK inhibition or IL-10 blockade abrogated these effects. Mechanistically, AICAR induced IL-10-producing Breg cells through AMPK-dependent suppression of mTOR signaling and mitochondrial reactive oxygen species while preserving oxidative phosphorylation. This reprogramming selectively enhanced regulatory B-cell function and suppressed STAT1 signaling without affecting STAT3. Functionally, these Breg cells suppressed TH1, TH2, and TH17 responses in an IL-10-dependent manner without expanding Foxp3+ regulatory T cells. In human peripheral blood mononuclear cells from patients with AD, AICAR restored immunometabolic coupling by increasing IL-10-producing B cells and reducing proinflammatory cytokine production.

CONCLUSION

These findings identify an AMPK-mTOR-redox metabolic checkpoint that governs regulatory B-cell function and restrains AD inflammation, linking metabolic control to immune regulation.

Для цитирования: Lee Seung Taek, Kim Ha Eun, Kim So-Yeon, Lee Jong Yeong, Nam Kyung-Hwa, Kim Sang-Hyun, Park Jun-Young, Choi Jin Kyeong. AMPK-driven immunometabolic reprogramming enhances CD19+CD21hiCD24hi regulatory B-cell-mediated suppression of atopic dermatitis.. The Journal of allergy and clinical immunology. 2026. DOI: 10.1016/j.jaci.2026.06.015.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.